<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03012230</url>
  </required_header>
  <id_info>
    <org_study_id>MC1534</org_study_id>
    <secondary_id>NCI-2016-02057</secondary_id>
    <secondary_id>MC1534</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT03012230</nct_id>
  </id_info>
  <brief_title>Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer</brief_title>
  <official_title>A Phase 1 Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given&#xD;
      together with pembrolizumab in treating patients with stage IV triple negative breast cancer&#xD;
      that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such&#xD;
      as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with&#xD;
      the ability of tumor cells to grow and spread. Ruxolitinib phosphate may stop the growth of&#xD;
      tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and&#xD;
      ruxolitinib phosphate together may work better in treating patients with stage IV triple&#xD;
      negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) of ruxolitinib phosphate (ruxolitinib) (JAK2&#xD;
      inhibition) in combination with fixed dosing of pembrolizumab (anti PD-1) in patients with&#xD;
      advanced/metastatic triple negative breast cancer (TNBC).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety profile of pembrolizumab in combination with ruxolitinib.&#xD;
&#xD;
      II. To estimate clinical tumor response in women with TNBC treated with pembrolizumab in&#xD;
      combination with ruxolitinib as measured by Response Evaluation Criteria in Solid Tumors&#xD;
      (RECIST) version (v)1.1.&#xD;
&#xD;
      EXPLORATORY/CORRELATIVE OBJECTIVES:&#xD;
&#xD;
      I. To assess tumor response with immune related (ir)RECIST and associations with PDJ&#xD;
      amplification, PD-L1, PD-L2, JAK2 and phosphorylated (p)STAT3 expression.&#xD;
&#xD;
      II. To determine the effect of combination targeted blockade on T- and B- cell immunity to&#xD;
      breast cancer tumor antigens.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of ruxolitinib phosphate.&#xD;
&#xD;
      Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 and ruxolitinib&#xD;
      phosphate orally (PO) twice daily (BID) on days 1-21. Courses repeat every 21 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study, patients are followed up every 3 or 6 months for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients. Assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 28 days after last dose of study drug</time_frame>
    <description>Assessed by NCI CTCAE version 4.0. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns (by cohort and overall). Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. The rate of grade 3 or higher non-hematologic adverse events, and the rate of grade 4 or higher adverse event (hematologic and non-hematologic) will be computed each with a 95% exact binomial confidence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as best objective status recorded from the start of the treatment until disease progression/recurrence. Assessed by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population (overall and by dose level).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of PDJ amplification, PD-L1, PD-L2, JAK2 expression and pSTAT3</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be explored for any associations with response to therapy. Statistical analysis of each biomarker will be primarily descriptive. Continuous biomarker levels will be explored in a graphical manner including mean plots and plots of change and percent change from baseline and other summary measures. Any potential relationships between the baseline level or change in the level of each biomarker and clinical outcome such as overall response will be further analyzed using Wilcoxon rank sum tests or logistic regression methods, as appropriate. Association between a dichotomized biomarker and overall response will be assessed using a chi-squared test. Comparisons with 1-sided p-values =&lt; 0.10 are considered significant.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Metastatic Malignant Neoplasm in the Bone</condition>
  <condition>Stage IV Breast Cancer AJCC v6 and v7</condition>
  <condition>Triple-Negative Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (pembrolizumab, ruxolitinib phosphate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pembrolizumab IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (pembrolizumab, ruxolitinib phosphate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pembrolizumab, ruxolitinib phosphate)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib Phosphate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (pembrolizumab, ruxolitinib phosphate)</arm_group_label>
    <other_name>INCB-18424 Phosphate</other_name>
    <other_name>Jakafi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Metastatic (stage IV) triple negative breast cancer that has progressed after at least&#xD;
             one prior chemotherapy regimen in the metastatic setting or refusal of chemotherapy in&#xD;
             the metastatic setting; non-measurable disease (i.e. bone metastases) is permitted&#xD;
&#xD;
          -  Histological confirmation of triple negative breast cancer defined as:&#xD;
&#xD;
               -  Her2/neu by fluorescence in situ hybridization (FISH) (ratio =&lt; 1.8) or&#xD;
                  immunohistochemistry (IHC) (0 or 1+)&#xD;
&#xD;
               -  Estrogen receptor (ER) and progesterone receptor (PR) expression &lt; 10%&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3 (obtained =&lt; 7 days prior to&#xD;
             registration)&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3 (obtained =&lt; 7 days prior to registration)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit normal (ULN) (obtained =&lt; 7 days prior to&#xD;
             registration)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5 x&#xD;
             ULN or &lt; 5 x ULN if organ involvement (obtained =&lt; 7 days prior to registration)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 5 x ULN (obtained =&lt; 7 days prior to registration)&#xD;
&#xD;
          -  Serum creatinine =&lt; 2 x ULN or 24 hour creatinine (Cr) clearance &gt; 60 ml/min (obtained&#xD;
             =&lt; 7 days prior to registration)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1&#xD;
&#xD;
          -  Ability to provide informed written consent and be able to adhere to the study visit&#xD;
             schedule and other protocol requirements&#xD;
&#xD;
          -  Willing to return to enrolling institution for follow-up (during the active monitoring&#xD;
             phase of the study)&#xD;
&#xD;
          -  Willing to provide blood samples for correlative research purposes&#xD;
&#xD;
          -  Has existing archived tissue and is willing to consent to providing sample for&#xD;
             correlative research purposes&#xD;
&#xD;
          -  Female subjects of childbearing potential should have a negative serum pregnancy =&lt; 7&#xD;
             days prior to registration&#xD;
&#xD;
          -  Female subjects of childbearing potential should be willing to use 2 methods of birth&#xD;
             control or be surgically sterile, or abstain from heterosexual activity for the course&#xD;
             of the study through 120 days after the last dose of study medication; subjects of&#xD;
             childbearing potential are those who have not been surgically sterilized or have not&#xD;
             been free from menses for &gt; 1 year; Note: abstinence is acceptable if this is the&#xD;
             usual lifestyle and preferred contraception for the subject&#xD;
&#xD;
          -  Male subjects of childbearing potential must agree to use an adequate method of&#xD;
             contraception starting with the first dose of study therapy through 120 days after the&#xD;
             last dose of study therapy; Note: abstinence is acceptable if this is the usual&#xD;
             lifestyle and preferred contraception for the subject&#xD;
&#xD;
          -  Radiographic or clinically measurable evidence of disease progression&#xD;
&#xD;
          -  Prior therapy with atezolizumab is acceptable providing that all atezolizumab-related&#xD;
             toxicities have resolved&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, active uncontrolled&#xD;
             infection, known positive for active infectious hepatitis, type A, B or C (past&#xD;
             infection allowed), or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements; Note: ongoing infection controlled on&#xD;
             antibiotics/antifungal/antiviral medications are allowed&#xD;
&#xD;
          -  Any of the following prior therapies:&#xD;
&#xD;
               -  Cytotoxic chemotherapy =&lt; 14 days prior to registration&#xD;
&#xD;
               -  Immunotherapy =&lt; 14 days prior to registration&#xD;
&#xD;
               -  Biologic therapy (i.e. antibody therapies) =&lt; 28 days prior to registration&#xD;
&#xD;
               -  Radiation therapy =&lt; 14 days prior to registration&#xD;
&#xD;
               -  Targeted therapies (i.e. PARP inhibitors, =&lt; 7 days or 5 half-lives whichever is&#xD;
                  shorter)&#xD;
&#xD;
               -  Receiving any other investigational agent which would be considered as a&#xD;
                  treatment for the primary neoplasm =&lt; 14 days prior to registration&#xD;
&#xD;
          -  Active uncontrolled central nervous system (CNS) metastases&#xD;
&#xD;
          -  Immunocompromised patients and patients known to be human immunodeficiency virus (HIV)&#xD;
             positive&#xD;
&#xD;
          -  Hypersensitivity to ruxolitinib or any of its excipients&#xD;
&#xD;
          -  Major surgery =&lt; 28 days prior to registration; Note: if subject received major&#xD;
             surgery, they must have recovered adequately from the toxicity and/or complications&#xD;
             from the intervention prior to starting therapy&#xD;
&#xD;
          -  Clinically significant heart disease, including the following:&#xD;
&#xD;
               -  Active severe angina pectoris prior to registration&#xD;
&#xD;
               -  Acute myocardial infarction prior to registration&#xD;
&#xD;
               -  New York Heart Association classification IV cardiovascular disease or&#xD;
                  symptomatic class III disease&#xD;
&#xD;
               -  Note: patients with any of the above may be allowed after discussion amongst the&#xD;
                  investigators including the principal investigator&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to registration&#xD;
&#xD;
          -  Hypersensitivity to pembrolizumab or any of its excipients&#xD;
&#xD;
          -  Has had a prior anti-cancer monoclonal antibody (mAb) =&lt; 4 weeks prior to registration&#xD;
             or who has not recovered (i.e., =&lt; grade 1 or at baseline level) from adverse events&#xD;
             due to agents administered more than 4 weeks earlier&#xD;
&#xD;
          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy who&#xD;
             has not recovered (i.e., =&lt; grade 1 or at baseline level) from adverse events due to a&#xD;
             previously administered agent&#xD;
&#xD;
               -  Note: subjects with =&lt; grade 2 neuropathy are an exception to this criterion and&#xD;
                  may qualify for the study&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires active treatment;&#xD;
             exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy or in situ cervical cancer&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment&#xD;
&#xD;
          -  Has known history of, or any evidence of active, non-infectious pneumonitis&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator&#xD;
&#xD;
          -  Any of the following because this study involves an investigational agent whose&#xD;
             genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are&#xD;
             unknown:&#xD;
&#xD;
               -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception&#xD;
&#xD;
               -  Is pregnant or breastfeeding, or expecting to conceive or father children within&#xD;
                  the projected duration of the trial, starting with the pre-screening or screening&#xD;
                  visit through 120 days after the last dose of trial treatment&#xD;
&#xD;
          -  Has received prior therapy with pembrolizumab, nivolumab, avelumab, durvalumab&#xD;
&#xD;
          -  Has received a live vaccine within 30 days of planned start of registration; Note:&#xD;
             seasonal influenza vaccines for injection are generally inactivated flu vaccines and&#xD;
             are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live&#xD;
             attenuated vaccines, and are not allowed&#xD;
&#xD;
          -  Evidence of pericardial involvement with metastatic breast cancer (effusion,&#xD;
             pericardial thickening)&#xD;
&#xD;
          -  Radiographic evidence of pulmonary lymphangitic spread of metastatic breast cancer&#xD;
&#xD;
          -  Evidence of bilateral pleural involvement with metastatic breast cancer (effusions,&#xD;
             pleural thickening)&#xD;
&#xD;
          -  Elevated serum lactate dehydrogenase level (LDH &gt; laboratory ULN) associated with any&#xD;
             clinical or radiographic evidence of intrathoracic metastatic breast cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald W Northfelt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>April 24, 2023</last_update_submitted>
  <last_update_submitted_qc>April 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03012230
org study id: MC1534
secondary id: NCI-2016-02057
secondary id: MC1534
secondary id: P30CA015083
nct id: NCT03012230
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given
      together with pembrolizumab in treating patients with stage IV triple negative breast cancer
      that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such
      as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
      the ability of tumor cells to grow and spread. Ruxolitinib phosphate may stop the growth of
      tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and
      ruxolitinib phosphate together may work better in treating patients with stage IV triple
      negative breast cancer.
PRIMARY OBJECTIVE:

      I. To determine the maximum tolerated dose (MTD) of ruxolitinib phosphate (ruxolitinib) (JAK2
      inhibition) in combination with fixed dosing of pembrolizumab (anti PD-1) in patients with
      advanced/metastatic triple negative breast cancer (TNBC).

      SECONDARY OBJECTIVES:

      I. To determine the safety profile of pembrolizumab in combination with ruxolitinib.

      II. To estimate clinical tumor response in women with TNBC treated with pembrolizumab in
      combination with ruxolitinib as measured by Response Evaluation Criteria in Solid Tumors
      (RECIST) version (v)1.1.

      EXPLORATORY/CORRELATIVE OBJECTIVES:

      I. To assess tumor response with immune related (ir)RECIST and associations with PDJ
      amplification, PD-L1, PD-L2, JAK2 and phosphorylated (p)STAT3 expression.

      II. To determine the effect of combination targeted blockade on T- and B- cell immunity to
      breast cancer tumor antigens.

      OUTLINE: This is a dose-escalation study of ruxolitinib phosphate.

      Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 and ruxolitinib
      phosphate orally (PO) twice daily (BID) on days 1-21. Courses repeat every 21 days in the
      absence of disease progression or unacceptable toxicity.

      After completion of study, patients are followed up every 3 or 6 months for up to 2 years.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Maximum tolerated dose
time frame: Up to 21 days
description: Defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients. Assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
measure: Incidence of adverse events
time frame: Up to 28 days after last dose of study drug
description: Assessed by NCI CTCAE version 4.0. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns (by cohort and overall). Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. The rate of grade 3 or higher non-hematologic adverse events, and the rate of grade 4 or higher adverse event (hematologic and non-hematologic) will be computed each with a 95% exact binomial confidence.
measure: Best response
time frame: Up to 2 years
description: Defined as best objective status recorded from the start of the treatment until disease progression/recurrence. Assessed by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population (overall and by dose level).
measure: Assessment of PDJ amplification, PD-L1, PD-L2, JAK2 expression and pSTAT3
time frame: Up to 2 years
description: Will be explored for any associations with response to therapy. Statistical analysis of each biomarker will be primarily descriptive. Continuous biomarker levels will be explored in a graphical manner including mean plots and plots of change and percent change from baseline and other summary measures. Any potential relationships between the baseline level or change in the level of each biomarker and clinical outcome such as overall response will be further analyzed using Wilcoxon rank sum tests or logistic regression methods, as appropriate. Association between a dichotomized biomarker and overall response will be assessed using a chi-squared test. Comparisons with 1-sided p-values =< 0.10 are considered significant.
arm group label: Treatment (pembrolizumab, ruxolitinib phosphate)
arm group type: Experimental
description: Patients receive pembrolizumab IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
intervention type: Other
intervention name: Laboratory Biomarker Analysis
description: Correlative studies
arm group label: Treatment (pembrolizumab, ruxolitinib phosphate)
intervention type: Biological
intervention name: Pembrolizumab
description: Given IV
arm group label: Treatment (pembrolizumab, ruxolitinib phosphate)
other name: Keytruda
other name: Lambrolizumab
other name: MK-3475
other name: SCH 900475
intervention type: Drug
intervention name: Ruxolitinib Phosphate
description: Given PO
arm group label: Treatment (pembrolizumab, ruxolitinib phosphate)
other name: INCB-18424 Phosphate
other name: Jakafi
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Donald W Northfelt
role: Principal Investigator
affiliation: Mayo Clinic
facility: 
country: United States
responsible party type: Sponsor
mesh term: Breast Neoplasms
mesh term: Triple Negative Breast Neoplasms
mesh term: Neoplasms
mesh term: Pembrolizumab